Skip to main
VTVT

vTv Therapeutics (VTVT) Stock Forecast & Price Target

vTv Therapeutics (VTVT) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 80%
Buy 20%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

vTv Therapeutics is a late-stage biopharmaceutical company with a strong pipeline of oral, small-molecule drug candidates focused on treating diabetes and other chronic diseases. The company's flagship candidate, cadisegliatin, has shown promising results in clinical trials as an adjunct therapy to insulin for people living with type 1 diabetes. With plans to initiate a Phase 2a Hybrid CATT1 trial before the end of 2026 and potential expansion into other indications, vTv's stock has a positive outlook with a price target of $42 and the potential for further upside. Key risks include safety concerns, lower than expected efficacy, competition, regulatory challenges, financing needs, and IP protection. However, with enthusiastic feedback from key opinion leaders and the potential for use in both adolescents and as a metabolic adjunct to emerging curative modalities, there is potential for vTv to reach new heights, with a revised price target of $57.

Bears say

vTv Therapeutics is facing numerous risks that could hinder the success of its clinical pipeline, including potential safety and efficacy issues in clinical trials, uncertainty of receiving marketing approval even with Special Assessment Protocol agreements, stiff competition in the T1D market, and potential delays in clinical trials due to reliance on third-party suppliers. Additionally, the company's financials and valuation may be negatively impacted by these risks, making it a risky investment. Therefore, as a financial analyst, a cautious approach is necessary when considering vTv Therapeutics's stock due to its inherent risks.

vTv Therapeutics (VTVT) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 80% of analysts recommend a Strong Buy, 20% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of vTv Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About vTv Therapeutics (VTVT) Forecast

Analysts have given vTv Therapeutics (VTVT) a Strong Buy based on their latest research and market trends.

According to 5 analysts, vTv Therapeutics (VTVT) has a Strong Buy consensus rating as of Aug 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $53.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $53.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

vTv Therapeutics (VTVT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.